Archive Issue Details

Abstract
In order to treat diseases like lymphoma, leukaemia, immune-deficiency disorders, congenital metabolic abnormalities, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes, more than 25,000 hematopoietic stem cell transplants (HSCTs) are carried out annually. Patients undergo extensive myeloablative chemoradiotherapy prior to transplantation, followed by stem cell "rescue." The patient's own hematopoietic stem cells, which are removed before to transplantation and reinfused fo

Files
View PDF